Our Read. Perpetua is a pre-production developer spending equity money ahead of a loan that is approved but not yet signed. The EXIM board approved a $2.9 billion loan on May 21, 2026 [1], and the company says full construction will not start until full financing is in place [2]. Meanwhile cash fell to $574.2 million at June 30 [3] and the quarter's loss was $97.5 million [4], almost all of it engineering and site work expensed rather than capitalized because the deposits have not met the accounting test [5]. Our read: the business is on its own stated plan, but the stock is a financing event, not an operating story, until loan documents are signed. Strength of belief: medium, because the plan is dated and public but the close conditions sit outside the company's control [6].

Positioning status. Not positioned, and no open hypothesis is on file for this name. The book does not hold PPTA. Watch. Looking for an entry at $20 with the EXIM documentation signed, a price inside the $18.66 to $30.67 band that has held eight in ten closes since March and above the $16.90 low of July 17, in a stock that fell 54.6% from its March high and has not recovered it.

The stock. At $23.50 the market values the company at $2.60 billion with no revenue and price to book of 4.3x against a peer median of 2.1x. That premium is a bet on the mine getting built. Direct capital cost is estimated at $2,576 million [7] against $574.2 million of cash, so the loan is the whole ballgame. The company itself lists insufficient committed financing as a risk [6].

What to watch. Definitive EXIM documentation, expected in the second half of 2026 [1]. Q3 spending of about $177 million [8] against the cash balance. The federal cases seeking to vacate the project approval.